What is Regeneron Pharmaceuticals?
Biotechnology and biologics company with $14.3B 2025 revenue scale and public-market buying capacity.
- Category
- Biotechnology and biologics
- Headquarters
- Tarrytown, NY
- Founded
- 1988
- Employees
- 14,000+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: REGN; Public company
What is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals is a public biotechnology and biologics company headquartered in Tarrytown, NY. Regeneron reported full-year 2025 revenues of $14.3 billion, while partner-recorded Dupixent global net sales reached $17.8 billion.
Regeneron Pharmaceuticals operates in biotechnology and biologics with a portfolio that includes Eylea HD, Eylea, Dupixent collaboration, Libtayo. Regeneron reported full-year 2025 revenues of $14.3 billion, while partner-recorded Dupixent global net sales reached $17.8 billion. The company employs about 14,000+ and trades as Nasdaq: REGN, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Regeneron Pharmaceuticals through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Regeneron Pharmaceuticals is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Regeneron Pharmaceuticals offer?
Regeneron Pharmaceuticals offers products and services across Eylea HD, Eylea, Dupixent collaboration, Libtayo and related healthcare workflows.
- Eylea HD· Ophthalmology
- Eylea· Ophthalmology
- Dupixent collaboration· Immunology
- Libtayo· Oncology
- Praluent· Cardiovascular
- Genetics Center and VelociSuite· Discovery platform
How does Regeneron Pharmaceuticals make money?
Regeneron Pharmaceuticals earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Regeneron Pharmaceuticals earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $14.3B 2025 of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Regeneron Pharmaceuticals improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals is led by Leonard S. Schleifer, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Leonard S. SchleiferCo-Founder, President and Chief Executive OfficerCEO since foundingBuilt Regeneron into a science-led commercial biotechnology company.
- George D. YancopoulosCo-Founder, President and Chief Scientific OfficerCSO since founding eraLeads discovery, VelociSuite technology, and R&D culture.
- Christopher FenimoreChief Financial OfficerCFO since 2021Oversees finance and investor operations.
- Marion McCourtExecutive Vice President and Head of CommercialCommercial leaderLeads commercialization across ophthalmology, immunology, oncology, and rare disease.
How do you contact Regeneron Pharmaceuticals's leadership?
Regeneron Pharmaceuticals publishes official Regeneron investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Regeneron investor-relations contact route; personal executive email format not verified- Leonard S. SchleiferCo-Founder, President and Chief Executive Officerofficial Regeneron investor-relations contact route
- George D. YancopoulosCo-Founder, President and Chief Scientific Officerofficial Regeneron investor-relations contact route
How much funding has Regeneron Pharmaceuticals raised?
Regeneron Pharmaceuticals is a mature public company, not a venture-backed startup. It trades as Nasdaq: REGN and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Regeneron Pharmaceuticals's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: REGN, $14.3B 2025 of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Regeneron Pharmaceuticals has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Regeneron Pharmaceuticals get here?
Regeneron Pharmaceuticals grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 1988Regeneron foundedLeonard Schleifer and George Yancopoulos build a science-led biotech.
- 1991IPORegeneron becomes public to fund long-horizon R&D.
- 2011Eylea approvedEylea becomes a major ophthalmology franchise.
- 2017Dupixent approvedThe Sanofi-Regeneron immunology collaboration scales globally.
- 2025$14.3B revenueRegeneron reports full-year revenue of $14.3 billion.
- 2026Dupixent global sales growthPartner-recorded Dupixent sales continue to expand.
Who are Regeneron Pharmaceuticals's competitors?
Regeneron Pharmaceuticals competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- SanofiA collaborator on Dupixent and a competitor across immunology and specialty medicines.
- AmgenCompetes in biologics, immunology, ophthalmology-adjacent innovation, and payer access.
- RocheCompetes in ophthalmology, oncology, and diagnostics-enabled specialty care.
- NovartisCompetes in ophthalmology, immunology, cardiovascular, and specialty medicine.
- Bristol Myers SquibbCompetes in immuno-oncology and specialty-biopharma accounts.
- AstraZenecaCompetes in oncology, respiratory/immunology, and biologics development.
Regeneron Pharmaceuticals — frequently asked questions
